Duration of therapy for actinic keratosis and outcome – PIQA study - 09/05/15
Carlos Serra-Guillén, MD, PhD, Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain; Salvador Arias-Santiago, MD, PhD, Department of Dermatology, Hospital Virgen de las Nieves, Granada, Spain; Juan Luis Artola, MD, Department of Dermatology, Hospital Galdakao, Vizcaya, Spain; Elena de las Heras, MD, PhD, Department of Dermatology, Hospital Ramón y Cajal, Madrid, Spain; Montserrat Fernández-Guarino, MD, PhD, Department of Dermatology, Hospìtal Central de la Cruz Roja, Madrid, Spain; José Luis López-Estebaranz, MD, PhD, Department of Dermatology, Fundación Hospital Alcorcón, Madrid, Spain; Leandro Martínez, MD, Department of Dermatology, Hospital Carlos Haya, Málaga, Spain; Dolores Sánchez-Aguilar, MD, Department of Dermatology, Hospital Clínico, Santiago de Compostela, Spain; Agustí Toll, MD, PhD, Department of Dermatology, Hospital del Mar, Barcelona, Spain; María Longo, MD, PhD, Department of Dermatology, Hospital Central de la Defensa, Madrid, Spain
Le texte complet de cet article est disponible en PDF. Study concept and data analysis Sponsored by LEO Pharma. |
Vol 72 - N° 5S1
P. AB183 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?